Logo do repositório
 

Vanadium complexes with hydrazone or thiosemicarbazone ligands as potential anti-mycobacterium tuberculosis agents

dc.contributor.authorSouza, Paula C. de [UNESP]
dc.contributor.authorMaia, Pedro I. S.
dc.contributor.authorBarros, Heloisa B. de [UNESP]
dc.contributor.authorLeite, Clarice Q. F. [UNESP]
dc.contributor.authorDeflon, Victor M.
dc.contributor.authorPavan, Fernando R. [UNESP]
dc.contributor.institutionUniversidade Estadual Paulista (Unesp)
dc.contributor.institutionUniversidade de São Paulo (USP)
dc.date.accessioned2015-12-07T15:36:01Z
dc.date.available2015-12-07T15:36:01Z
dc.date.issued2015
dc.description.abstractTuberculosis (TB) is an infectious disease caused mainly by Mycobacterium tuberculosis (MTB) and still an important public health problem worldwide. Some factors like the emergence of multidrug resistant (MDR) and extensively drug-resistant (XDR) strains make urgent the research of new active compounds. Searching for new inorganic compounds against TB, three new dioxovanadium(V) complexes were obtained upon reaction of [VO(acac)2] with hydrazone and thiosemicarbazone ligands derived from di-2-pyridyl ketone. Spectroscopic studies and X-ray crystallography revealed asymmetrically oxo bridged binuclear complexes of the type [{VO(L(1,2))}2(μ-O)2], involving the hydrazone ligands, while a mononuclear square pyramidal complex of the type [VO2(L(3))] was formed with the thiosemicarbazone ligand. The compounds were tested against M. tuberculosis and three of them, with MICs values between 2.00 and 3.76 μM were considered promising for TB treatment. Such MIC values are comparable or better than those found for some drugs currently used in TB treatment.en
dc.description.affiliationFaculdade de Ciências Farmacêuticas (FCFAR), Universidade Estadual Paulista (UNESP), Araraquara, SP, Brasil
dc.description.affiliationInstituto de Química de São Carlos, Universidade de São Paulo (USP), São Carlos, SP, Brasil
dc.description.affiliationUnespFaculdade de Ciências Farmacêuticas (FCFAR), Universidade Estadual Paulista (UNESP), Araraquara, SP, Brasil
dc.description.sponsorshipConselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)
dc.description.sponsorshipFundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)
dc.description.sponsorshipIdCNPq: 406827/2012-5
dc.description.sponsorshipIdFAPESP: 2009/54011-8
dc.description.sponsorshipIdFAPESP: 2013/14957-5
dc.description.sponsorshipIdFAPESP: 2014/11586-9
dc.format.extent66-72
dc.identifierhttp://dx.doi.org/10.2174/1574884708666131229124748
dc.identifier.citationCurrent Clinical Pharmacology, v. 10, n. 1, p. 66-72, 2015.
dc.identifier.doi10.2174/1574884708666131229124748
dc.identifier.issn2212-3938
dc.identifier.pubmed24433444
dc.identifier.urihttp://hdl.handle.net/11449/131469
dc.language.isoeng
dc.publisherBentham Science Publishers
dc.relation.ispartofCurrent Clinical Pharmacology
dc.rights.accessRightsAcesso restritopt
dc.sourcePubMed
dc.subjectDioxovanadium(V)en
dc.subjectHydrazoneen
dc.subjectMycobacterium tuberculosisen
dc.subjectNew antituberculosis compoundsen
dc.subjectThiosemicarbazoneen
dc.titleVanadium complexes with hydrazone or thiosemicarbazone ligands as potential anti-mycobacterium tuberculosis agentsen
dc.typeArtigopt
dcterms.rightsHolderBentham Science Publishers
dspace.entity.typePublication
relation.isDepartmentOfPublication5004bcab-94af-4939-b980-091ae9d0a19e
relation.isDepartmentOfPublication.latestForDiscovery5004bcab-94af-4939-b980-091ae9d0a19e
relation.isOrgUnitOfPublication95697b0b-8977-4af6-88d5-c29c80b5ee92
relation.isOrgUnitOfPublication.latestForDiscovery95697b0b-8977-4af6-88d5-c29c80b5ee92
unesp.campusUniversidade Estadual Paulista (UNESP), Faculdade de Ciências Farmacêuticas, Araraquarapt
unesp.departmentCiências Biológicas - FCFpt

Arquivos